Cromos Pharma supporting psoriasis clinical research breakthroughs

August is Psoriasis Awareness Month. Cromos Pharma is using this opportunity to underline its commitment to supporting clinical trials to develop new and innovative treatments to improve the lives of millions of psoriasis sufferers around the world. 

Immune disorder affecting 125 million people worldwide

Psoriasis is a complex immune system disorder in which white blood cells, known as T cells, mistakenly attack skin cells, which causes the skin-cell production process to go into overdrive. This results in a build-up of skin cells causing red, scaly patches on the skin. This manifestation is a sign of systematic inflammation and the condition has several co-morbidities, including inflammatory bowel disease, arthritis, depression, cardiovascular disease and metabolic disease.

Types of Psoriasis

  • Plaque —The most common form of psoriasis, accounting for approximately 80% of all cases. Plaque psoriasis presents as inflamed red patches covered with a silvery, white build-up of dead skin cells. Affected skin can be itchy and painful and occur on any part of the body most commonly knees, elbows, and scalp.
  • Guttate — The second most common form it occurs in about 10% of people. It usually presents in childhood and is characterized by small, pink, dot-like lesions on the torso, arms, and legs.
  • Inverse — Manifests as areas of red, shiny, and inflamed skin found in body folds, such as behind the knee, under the armpits or breasts, and in the groin. It may occur with other types of psoriasis on the body. 
  • Pustular —This rare form of the disease generally occurs in adults. It is characterized by white or pus-filled blisters surrounded by red, inflamed skin on the hands or feet.
  • Erythrodermic —This is a severe and very rare type of psoriasis occurring in about 3% of cases. It presents as widespread redness over large sections of the body and causes the skin to peel off. 

Triggers for psoriasis

The exact cause of psoriasis is not known. Research has found in those with a genetic predisposition for the disease, several factors may trigger psoriasis. Common triggers include: infections (strep), weather (cold, dry conditions), injury to the skin, stress, smoking, heavy alcohol consumption, and certain medications.

Treatments for psoriasis

At present, there is no cure for psoriasis but there are several classes of medications designed to treat psoriatic symptoms. These include topical ( e.g. Corticosteroids, Vitamin D analogues, Calcineurin inhibitors and cold tar), light (Sunlight, UVB, Psoralen plus ultraviolet A ), and systemic therapies (e.g. Cyclosporine and Methotrexate). 

Biologics and Biosimilars

In the last decade biologic drugs (e.g. etanercept (Enbrel), infliximab (Remicade), adalimumab (Humira), ustekinumab (Stelara)) have been developed for autoimmune disorders including psoriasis. These drugs have proven to be highly effective for those suffering with moderate to severe psoriasis. However, they are costly and not always covered by health insurers or national health systems. The development of biosimilars of these blockbuster drugs has the potential to dramatically reduce costs and increase access for the millions of individuals with psoriasis across the globe.

Cromos Pharma and dermatological clinical research

Cromos Pharma has a strong track record in managing clinical trials designed to find effective treatments for psoriasis and wide-ranging expertise in dermatological clinical research. In addition, it possesses experience in supporting clinical programs for the development of biologics and biosimilars.  

Read our Psoriasis case study here


Cromos Pharma is a US-based, international contract research organization with 16 years’ experience in delivering fully integrated clinical research solutions, in all aspects of clinical trials, in all clinical phases, across a wide range of therapeutic areas. Our expert team boasts wide-ranging expertise in study design, medical writing, regulatory affairs, site management, patient recruitment and data management. From bioequivalence studies, biosimilars and generics to successfully managing oncology, neurology, dermatology clinical trials, our team provides full service solutions to international pharma and biotech, in high recruiting regions, with high quality data assured.

Established in 2004, Cromos Pharma has strong regional experience in Central and Eastern Europe, supported by an extensive network of offices. Its international HQ is in Portland, Oregon, USA and EU HQ in Dublin, Ireland. 

Find out more about how Cromos Pharma can support your next clinical project by emailing








To arrange an introductory meeting and find out how our experience can benefit your next clinical project.